Smith Quentin R, Mandula Haritha, Parepally Jagan Mohan R, Oki Jun, Thomas Fancy, Thorsheim Helen R, Al-Ahmad Abraham J, Abbruscato Thomas J, Ask Per, Hage David S, Robinson Peter J
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Fluids Barriers CNS. 2024 Dec 17;21(1):100. doi: 10.1186/s12987-024-00584-y.
Cerebral blood flow normally places a limit on the magnitude of brain vascular permeability (P) that can be measured in vivo. At normal cerebral blood flow, this limit falls at the lower end of lipophilicity for most FDA-approved CNS drugs. In this study, we report on two methods that can be used to overcome this limitation and measure brain vascular permeability values that are up to ~1000 times higher using the in situ brain perfusion technique.
Rat brain was perfused with physiological saline at increased flow rate and in the presence of various concentrations of plasma protein, serum albumin or alpha-acid glycoprotein. Plasma protein was added to the saline perfusion fluid to lower extraction into the measurable range using the Crone Renkin "diffusion-flow" equation to calculate brain PS.
Cerebrovascular P was determined for 125 solutes, of which 78 showed little or no evidence of active efflux transport. Fifty of the solutes were in the lipophilicity zone (Log P 1-5) of most FDA-approved CNS drugs. Care was taken to ensure the integrity of the brain vasculature during perfusion and to measure flow accurately using markers that had been verified for the flow rates. The results showed a linear relationship between Log P and Log P over ~10 orders of magnitude with values for diazepam, estradiol, testosterone, and other agents that exceed prior published values by fivefold to 200-fold.
The results show that brain vascular permeability can be measured directly in vivo for highly lipophilic solutes and the PS values obtained match reasonably with that predicted by the Crone-Renkin flow diffusion equation with care taken to validate the accuracy for the component measurements and with no need to invoke "enhanced" or "induced" dissociation.
脑血流量通常会对体内可测量的脑血管通透性(P)的大小设置限制。在正常脑血流量下,对于大多数美国食品药品监督管理局(FDA)批准的中枢神经系统(CNS)药物而言,这一限制处于亲脂性的下限。在本研究中,我们报告了两种可用于克服这一限制的方法,使用原位脑灌注技术可测量高达约1000倍的脑血管通透性值。
以增加的流速并在存在各种浓度的血浆蛋白、血清白蛋白或α-酸性糖蛋白的情况下,用生理盐水灌注大鼠脑。将血浆蛋白添加到盐水灌注液中,以降低提取率至可测量范围,使用克朗-伦金“扩散-流量”方程计算脑PS。
测定了125种溶质的脑血管P,其中78种几乎没有或没有主动外排转运的证据。50种溶质处于大多数FDA批准的CNS药物的亲脂性区域(Log P 1-5)。在灌注过程中注意确保脑血管系统的完整性,并使用已针对流速进行验证的标记物准确测量流量。结果显示Log P与Log P在约10个数量级上呈线性关系,地西泮、雌二醇、睾酮和其他药物的值比先前发表的值高出5倍至200倍。
结果表明,对于高亲脂性溶质可在体内直接测量脑血管通透性,并且在注意验证各成分测量准确性且无需引入“增强”或“诱导”解离的情况下,获得的PS值与克朗-伦金流量扩散方程预测的值合理匹配。